Okunieff P
Department of Radiation Medicine, Massachusetts General Hospital, Boston 02114.
Am J Clin Nutr. 1991 Dec;54(6 Suppl):1281S-1283S. doi: 10.1093/ajcn/54.6.1281s.
In studies of isotransplants of a murine fibrosarcoma, FSaII, ascorbic acid administered 50 min before whole-body radiation significantly increased the dose of radiation required to cause a fatal radiation syndrome and the dose of radiation required to obtain skin desquamation. A single intraperitoneal dose of 4.5 g/kg body wt was not cytotoxic and did not affect the radiation dose required to control 50% of tumors or to achieve remissions. The mechanism of this differential radiomodification of normal tissue sensitivity and tumor tissue response is unclear. The data suggest that after high-dose ascorbic acid the radiation dose given to cancer patients could be increased without increasing acute complications but with an expected increase in tumor-control probability. However, only acute radiation reaction endpoints have been studied. Application of these findings to humans must therefore await further studies confirming that late reacting tissues are similarly protected by ascorbic acid.
在对小鼠纤维肉瘤FSaII的同基因移植研究中,在全身辐射前50分钟给予抗坏血酸,可显著增加导致致命辐射综合征所需的辐射剂量以及出现皮肤脱屑所需的辐射剂量。腹腔内单次给予4.5 g/kg体重不会产生细胞毒性,也不会影响控制50%肿瘤或实现缓解所需的辐射剂量。正常组织敏感性和肿瘤组织反应这种差异辐射修饰的机制尚不清楚。数据表明,给予高剂量抗坏血酸后,癌症患者接受的辐射剂量可以增加,而不会增加急性并发症,但预计肿瘤控制概率会增加。然而,仅研究了急性辐射反应终点。因此,要将这些发现应用于人类,必须等待进一步研究证实抗坏血酸对晚期反应组织有类似的保护作用。